 Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, today announced that the MELANI-01 trial has been placed on clinical hold by the U.S. Food and Drug Administration FDA. This clinical hold which impacts one of the three Cellectis product candidates currently in clinical studies, was initiated following the submission of a safety report regarding one patient enrolled in the MELANI-01 study at dose level two DL2, with relapsed and refractory multiple myeloma. Clinical evaluation of the case remains ongoing and additional details as to the immediate and underlying causes of this event are being collected. 